Week Ending July 19, 2021

Delay in Surgical Intervention for Early-Stage Non-Small Cell Lung Cancer Increases Risk for Recurrence
“Patients with stage I non-small cell lung cancer (NSCLC) should undergo expedited surgical intervention to reduce recurrence risk. These findings were published in JAMA Network Open.”

Preventing lung cancer’s unwelcome return
“When a doctor gives a patient antibiotics for a bacterial infection, they usually require them to finish the entire treatment, even when symptoms go away. This is to ensure the drugs kill off any remaining bacteria. Cold Spring Harbor Laboratory (CSHL) Visiting Scientist Raffaella Sordella investigated a similar problem that occurs in some lung cancers.”

Liquid Biopsy-Guided Therapy Improves Survival in Lung Cancer
“Liquid biopsies can match non-small cell lung cancer (NSCLC) patients to life-prolonging targeted therapy and have prognostic importance. Targeted therapy has transformed the treatment landscape of NSCLC and fundamentally made it possible, by next-generation sequencing of tissue, to match patients to therapies that prolong overall survival (OS).”

Efficacy and Feasibility of Neoadjuvant Osimertinib Demonstrated in Early-Stage EGFR+ Lung Adenocarcinoma
“Neoadjuvant osimertinib (Tagrisso) is effective and feasible for use as treatment for patients with stage II-IIIB EGFR-mutant lung adenocarcinoma, according to interim analysis results of the NEOS study.”

Lung Cancer Repository Trial Presents Early Data
“The ongoing PGC (Prospective Clinico-Genomic) study is exploring how various technologies, such as electronic health records (EHRs), clinical images of patients and liquid biopsies, can be integrated to streamline and simplify clinical trials for people with advanced lung cancer. Data from the trial, which has enrolled patients at 23 sites from 19 community oncology practices across the country, were presented at the International Association for the Study of Lung Cancer (IASLC) 2021 World Congress on Lung Cancer.”

Advances Propel Lung Cancer Paradigms Forward to Improved Outcomes and Quality of Life
“Among a plethora of novel immunotherapeutic and targeted agents, the treatment landscapes for small cell lung cancer and non–small cell lung cancer have witnessed a rapid expansion that has led to improved survival and quality of life for patients, including a wider range of patients who harbor molecular abnormalities.”

Pembrolizumab Provides Durable Survival Benefit in Metastatic Non-Small Cell Lung Cancer With High PD-L1 Expression
“First-line therapy with pembrolizumab provides a long-term overall survival (OS) benefit over chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) and high PD-L1 expression, according to trial results published in the Journal of Clinical Oncology.”

Have You Been Screened for Lung Cancer?
“Screening for lung cancer can save lives, but the majority of people who qualify for the free exam aren’t taking advantage of it.”

Stephen Liu, MD, on the Potential Treatment Impact of Amivantamab Plus Lazertinib in EGFR+ NSCLC at ASCO 2021